RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Visterra will present preclin data on VIS410, monoclonal antibody for influenza A at Intl. Society for Influenza & Other Respiratory Virus Diseases.

The Advisory Committee on Immunization Practices (ACIP), made up of members recently hand-selected by Health and Human ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which could set the stage for the company’s combination COVID-19/influenza ...

The majority of seasonal influenza infections result in mild illness; however, some infections result in severe disease, which may include rapidly progressive pneumonia, respiratory failure and death.

Preclinical results presented at ICAAC 2013 demonstrated the ability of VIS410 to neutralize influenza strains with pandemic potential, H5N1 and H7N9VIS410, a novel engineered human antibody ...

Visterra presents prophylactic and therapeutic efficacy data of VIS410 against the H5N1 (Avian Flu) influenza strain in Hanoi, Viet Nam For Visterra, Inc.Kathryn Morris, 845-635-9828 ...

It was called the Spanish influenza. ... So, in the world press, the only nation whose plight, vis-á-vis flu, was widely publicized was Spain’s, so everybody said it’s the Spanish flu.

Of the 25 children who died from flu, only one was vaccinated, the state health commissioner, Dr. James V. McDonald, noted. Five were too young to be vaccinated, he said in a statement.

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...